Is Oral Micronized Progesterone (Prometrium) Safe During Pregnancy?

What Is Oral Micronized Progesterone and Why Is It Used in Pregnancy?

Oral micronized progesterone (OMP) is a bioidentical form of progesterone, meaning its molecular structure is identical to the progesterone your ovaries produce. It comes as a soft-gel capsule (Prometrium and generics) containing micronized progesterone suspended in peanut oil, which allows for better intestinal absorption compared with older crystalline formulations.

Progesterone is the hormone that maintains the uterine lining after ovulation and is absolutely required to sustain a pregnancy through the first trimester, until the placenta takes over progesterone production at roughly 8 to 10 weeks of gestation. When progesterone levels are insufficient, the uterine environment may not adequately support implantation or early fetal development.

OMP is FDA-approved only for endometrial protection in postmenopausal women on estrogen therapy and for secondary amenorrhea. It is not FDA-approved for use in pregnancy. Despite this, reproductive endocrinologists and OB-GYNs routinely prescribe it off-label for luteal phase support in ART cycles, threatened miscarriage, and recurrent pregnancy loss, because the human reproductive safety data accumulated over 30 years are generally reassuring.

Why the Oral Route Matters for Women

When you take OMP by mouth, the liver metabolizes a large portion of it before it reaches systemic circulation, a process called first-pass metabolism. This means oral dosing produces relatively low serum progesterone levels but generates sedating neurosteroid metabolites (allopregnanolone), which is why the capsule is typically taken at bedtime. Vaginal administration bypasses first-pass metabolism, produces higher local uterine concentrations, and causes less sedation, which is why many clinicians prefer the vaginal route for luteal support even when using Prometrium capsules vaginally (an off-label route for an off-label use).

Female Conditions That Often Lead to OMP Prescribing in Pregnancy

OMP touches several women-specific diagnoses:

• Luteal phase defect: Inadequate progesterone output after ovulation, more common in women with PCOS or hypothalamic dysfunction.
• PCOS: Women with polycystic ovary syndrome often have disordered ovulation and may have suboptimal luteal progesterone.
• Recurrent pregnancy loss (RPL): Defined as two or more clinical pregnancy losses; affects roughly 1 to 2 percent of couples trying to conceive.
• ART and IVF cycles: After egg retrieval, the corpus luteum is disrupted, so exogenous progesterone is required for luteal support in virtually every IVF cycle.
• Threatened miscarriage: Vaginal bleeding in the first trimester with a viable pregnancy on ultrasound.

What the Clinical Trials Actually Show

The evidence base for OMP in pregnancy is specific enough that you deserve more than a vague "studies support it." Here is what the named trials found.

The PROMISE Trial (2015)

The PROMISE trial, published in the New England Journal of Medicine, randomized 836 women with unexplained recurrent miscarriage (two or more prior losses) to OMP 400 mg vaginally twice daily or placebo, starting before 6 weeks of gestation and continuing to 12 weeks. The live birth rate was 65.8 percent in the progesterone group versus 63.3 percent in the placebo group, a difference that was not statistically significant. This trial is important because it tells you OMP does not appear to help in unexplained RPL when there is no active bleeding at the time of starting treatment.

The PRISM Trial (2019)

The PRISM trial, also published in the New England Journal of Medicine, enrolled 4,153 women presenting with first-trimester vaginal bleeding (threatened miscarriage). Women randomized to OMP 400 mg vaginally twice daily had a live birth rate of 75 percent compared with 72 percent in the placebo group, an absolute difference of 3 percentage points. Among the pre-specified subgroup of women with one or more prior miscarriages, the live birth rate was 72 percent with OMP versus 57 percent with placebo, a clinically meaningful difference of 15 percentage points. This subgroup finding is why many clinicians now offer OMP to women presenting with threatened miscarriage who also have a history of prior loss.

ART and IVF Cycles

In IVF, luteal progesterone support is not optional. Without exogenous progesterone after egg retrieval, the endometrium will not support implantation. Vaginal progesterone (micronized or gel) has historically been preferred for IVF luteal support based on the uterine first-pass effect, but oral OMP has been studied as well. A 2021 Cochrane review of progesterone for luteal phase support in ART cycles found that vaginal progesterone remains the most studied route, and head-to-head data comparing oral versus vaginal OMP in IVF are limited. Most fertility clinics in the United States use vaginal progesterone suppositories or Endometrin for IVF cycles rather than oral OMP, though some protocols layer in oral OMP.

What Is Extrapolated Versus Directly Studied

Women have been historically underrepresented in drug trials, and pregnancy trials face added complexity. The PROMISE and PRISM trials used vaginal OMP, not oral OMP. Most first-trimester luteal support data come from vaginal formulations. When clinicians prescribe oral Prometrium capsules for luteal support or threatened miscarriage, they are often extrapolating from vaginal progesterone data, because oral OMP has not been evaluated in large randomized controlled trials for these pregnancy indications specifically. This distinction matters: the reassuring trial evidence does not map perfectly onto oral dosing.

Pregnancy Safety: What the Data Say

A practical way to think about progesterone safety in pregnancy is to separate three questions: Does it harm the fetus? Does it cause structural birth defects? Does it cause other adverse pregnancy outcomes?

Teratogenicity Data

Early synthetic progestins (not the same as bioidentical progesterone) were associated with virilization of female fetuses in the 1950s and 1960s. Oral micronized progesterone is a different compound entirely. The FDA prescribing information for Prometrium notes that animal reproduction studies with micronized progesterone did not show evidence of fetal harm, and available human data do not indicate a drug-associated risk of major birth defects or miscarriage. The historical FDA Pregnancy Category for Prometrium was B, meaning animal studies were reassuring and adequate controlled studies in pregnant women were not available.

Endogenous progesterone is, of course, required for pregnancy maintenance. The concern about teratogenicity with bioidentical progesterone is low based on both biological plausibility and accumulated observational data.

First-Trimester Exposure Registries

No large prospective registry has identified a pattern of birth defects attributable to OMP specifically. A 2012 analysis in Fertility and Sterility examining ART outcomes in women using vaginal micronized progesterone found no increase in congenital anomalies compared with the general ART population. While this data applies to vaginal micronized progesterone in ART cycles and not to oral OMP in natural pregnancy, the structural molecule is identical.

The Peanut Oil Warning

This safety point deserves its own emphasis because it is often missed in general discussions. Prometrium capsules contain peanut oil as the carrier. If you have a peanut allergy, you must not take Prometrium. Your clinician should ask about nut allergies before prescribing, and you should confirm this before filling any prescription. Generic oral micronized progesterone capsules may use different carrier oils; verify with your pharmacist.

When OMP Should Not Be Used in Pregnancy

OMP is not appropriate in every situation. Absolute contraindications during pregnancy include:

• Known or suspected peanut allergy (for Prometrium specifically)
• Undiagnosed vaginal bleeding where ectopic pregnancy has not yet been ruled out
• Known missed abortion (blighted ovum) where the pregnancy has already failed

OMP is not a treatment for ectopic pregnancy and will not prevent miscarriage in a pregnancy that has already failed. Before starting OMP for bleeding in early pregnancy, your clinician should confirm a viable intrauterine pregnancy by ultrasound.

Dosing by Life Stage and Clinical Situation

Progesterone dosing in pregnancy is not one-size-fits-all. The right dose depends on why you are taking it and how far along you are.

Luteal Phase Support (Trying to Conceive or Early IVF)

For natural cycles with suspected luteal phase defect, oral OMP is typically prescribed at 100 to 200 mg at bedtime starting after ovulation confirmation (day 14 to 16 of a 28-day cycle) and continued until a negative pregnancy test or, if pregnant, until 10 to 12 weeks gestation. Because of the sedating metabolites, bedtime dosing is standard.

Threatened Miscarriage (Based on PRISM Protocol)

The PRISM trial protocol used 400 mg vaginally twice daily. Clinicians prescribing oral OMP for this indication often use 200 mg orally twice or three times daily, though direct oral-dose equivalence to the vaginal PRISM dose has not been established in a clinical trial. This is an area where you should ask your clinician specifically what evidence base they are drawing from.

IVF Cycles

Protocols vary by clinic. Vaginal micronized progesterone (200 mg three times daily or equivalent) remains the standard for most IVF programs in the United States, per standard reproductive endocrinology practice. Oral OMP is sometimes added for additional systemic support but is rarely the sole luteal support agent in IVF.

Perimenopause and Reproductive-Age Women Not Pregnant

OMP has a distinct and well-supported role in perimenopause for endometrial protection and sleep, but that is outside the scope of this pregnancy-focused article.

Oral Micronized Progesterone and Breastfeeding

Breastfeeding safety data for OMP are limited but generally reassuring. According to LactMed, progesterone does transfer into breast milk in small amounts, but because progesterone is a normal component of human milk and is inactivated by the infant's gut, the clinical significance is considered low. Serum levels in breastfed infants whose mothers took progesterone have not been measured in controlled studies.

The LactMed entry for progesterone notes that oral progesterone was associated with reduced milk production in some early studies, which is physiologically plausible because high progesterone levels suppress lactation before delivery. Women who are trying to establish or maintain milk supply should discuss timing and necessity of OMP with their clinician and a lactation consultant. If OMP is needed postpartum (for example, for luteal support in a subsequent ART cycle while still breastfeeding), use should be monitored alongside milk supply.

No documented cases of harm to a breastfed infant from maternal OMP use appear in the published literature, but the evidence base is thin. This is an area where the honest answer is: risk appears low based on available data, but controlled breastfeeding studies are lacking.

Who This Is Right For and Who Should Think Twice

Women Who May Benefit from OMP in Pregnancy

• Women with confirmed luteal phase defect trying to conceive in natural cycles
• Women undergoing IVF or other ART cycles (progesterone support is essentially universal in this group)
• Women with a history of one or more prior miscarriages who present with first-trimester bleeding (supported by the PRISM subgroup analysis)
• Women with PCOS who have irregular ovulation and suspected suboptimal luteal function
• Women with a prior diagnosis of recurrent pregnancy loss who are working with a reproductive endocrinologist

Women Who Should Discuss Alternatives or Proceed Carefully

• Women with a peanut allergy (vaginal progesterone preparations without peanut oil, such as Endometrin or compounded progesterone in alternative bases, may be more appropriate)
• Women with unexplained recurrent miscarriage without bleeding at presentation (the PROMISE trial did not show benefit in this group)
• Women whose early pregnancy loss is chromosomally abnormal (the majority of first-trimester losses; progesterone cannot correct an aneuploid pregnancy)
• Women with undiagnosed bleeding where ectopic pregnancy has not been excluded

Life-Stage Nuances

Reproductive years / trying to conceive naturally: OMP for luteal phase support is often the first pharmacologic step, prescribed by OB-GYNs and reproductive endocrinologists. Monitoring serum progesterone levels on day 7 post-ovulation (target above 10 ng/mL, though reference ranges vary) helps confirm whether supplementation is achieving adequate levels.

ART cycles: Progesterone support is mandatory. The question is route and formulation, not whether to use it.

Postpartum: OMP use postpartum should be weighed against potential effects on milk supply. Progestin-only contraceptive options (such as the progestin-only pill or IUD) are generally preferred for postpartum contraception if progesterone supplementation is not clinically indicated.

Perimenopause: Not a pregnancy indication, though perimenopausal women using OMP for sleep or endometrial protection who unexpectedly conceive should contact their clinician immediately for dosing guidance.

What to Ask Your Clinician Before Starting OMP in Pregnancy

Before filling a Prometrium prescription in early pregnancy, these are specific questions worth raising:

1. What is the specific indication for prescribing OMP in my case?
2. Is there trial-level evidence for oral OMP at this dose, or is this extrapolated from vaginal data?
3. Has ectopic pregnancy been ruled out with ultrasound and HCG trending?
4. Do I have a peanut allergy that makes Prometrium specifically unsafe for me?
5. What serum progesterone level are you targeting, and when will you check it?
6. How long will I take OMP and at what point will we taper or stop?
7. If I am breastfeeding or plan to breastfeed, how does OMP affect milk supply?

ACOG Practice Bulletin No. 200 on Early Pregnancy Loss acknowledges the ongoing uncertainty around progesterone supplementation for miscarriage prevention and recommends shared decision-making between patient and clinician, particularly for women with recurrent loss and current bleeding.

Pregnancy and Lactation Safety: Required Summary

Pregnancy: OMP (Prometrium) is not FDA-approved for use during pregnancy. Historical FDA Pregnancy Category: B. Available human reproductive data do not indicate a drug-associated risk of major birth defects. Bioidentical progesterone is required for pregnancy maintenance and is produced endogenously by the corpus luteum and then the placenta. Teratogenicity risk from OMP appears low based on accumulated observational data and biological plausibility, but large randomized trials in oral OMP specifically during pregnancy are lacking. The FDA Prometrium label should be reviewed for the most current prescribing information.

Lactation: Progesterone transfers into breast milk in small amounts. The infant dose is considered low and clinically unlikely to cause harm, but controlled breastfeeding pharmacokinetic studies are absent. High-dose progesterone may suppress milk production. Review LactMed progesterone entry for the current evidence summary.

Contraception requirement: OMP is not a contraceptive. Women taking OMP for luteal support who do not want to become pregnant must use reliable contraception. Women with PCOS who are anovulatory may assume they cannot conceive but are at risk during cycles where ovulation unexpectedly occurs.

Peanut allergy: Prometrium capsules contain peanut oil. Women with peanut allergy must not use Prometrium. Vaginal progesterone preparations using alternative carriers are available.